Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000947 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 850
- Enrollment target
NCT00000947 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 850 participants.
The verdict
NCT00000947, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 850 participants
- Enrollment target
Study Summary
This study is designed to find out whether HIV-positive patients whose immune systems have improved after receiving anti-HIV treatment should take azithromycin to prevent Mycobacterium avium complex (MAC) disease. This study also examines the possibility of putting off MAC prevention treatment in patients who respond well to anti-HIV drug therapy. Azithromycin is approved for the prevention of MAC disease in people with HIV and low CD4 cell counts. However, some people who have taken azithromycin have been found to carry antibiotic-resistant bacteria (germs that can grow despite the presence of drugs used to kill them). It is not known whether the risks associated with taking azithromycin outweigh the risk of getting MAC disease.
Interventions
- DRUG Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Est. Completion | 2000-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000947
The ClinicalTrials.gov registry entry for NCT00000947 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azithromycin is the first listed.
NCT00000947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000947 about?
NCT00000947 is a clinical study titled "A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients". This study is designed to find out whether HIV-positive patients whose immune systems have improved after receiving anti-HIV treatment should take azithromycin to prevent Mycobacterium avium complex (MAC) disease. This study also examines the possibility of putting off MAC prevention treatment in pa...
What is the current status of trial NCT00000947?
This trial is currently completed. It is a NA study. The enrollment target is 850 participants. Estimated completion is 2000-07.
What interventions are being tested in trial NCT00000947?
The interventions under investigation include: Azithromycin (DRUG).
Who is sponsoring clinical trial NCT00000947?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.